Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Instil Bio, Inc. (NQ: TIL )

23.01 -0.84 (-3.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Instil Bio, Inc.

< Previous 1 2 3 4 5 Next >
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
From Instil Bio
Via GlobeNewswire
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy. 
Via The Motley Fool
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
These relatively small companies are developing new cancer therapies that could generate billions in annual sales. 
Via The Motley Fool
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
Via The Motley Fool
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
From Instil Bio
Via GlobeNewswire
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy. 
Via The Motley Fool
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... 
Via Talk Markets
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
From Instil Bio
Via GlobeNewswire
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023. 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023. 
Via InvestorPlace
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells 
From Instil Bio
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.